Portfolio Lab

Exelixis, Inc.

  • Stock
  • Ticker EXEL
  • ISIN US30161Q1040
  • Nasdaq

Health care · Biotechnology · USA

$64.63 −1.82%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Exelixis, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

EXELGlobal equities (VT)

$10,000 grew to $37,641. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −57.2% in 10/2018, measured from the peak in 01/2018. It took 82 months to get back to the old peak.

1-year return
+54.7%
5-year return p.a.
+29.1%
10-year return p.a.
+14.2%
Volatility p.a.
40.6%
Largest decline
−57.2%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end01/202504/202507/202510/202501/202604/202607/202610/2026
Income statement
Revenue567555568598599611629659
Gross profit547536549579572591608632
Operating income163187214237235251248268
EBITDA171194221244242258255275
Net income140160185194245210212218
Earnings per share0.480.550.650.690.880.790.820.85
Balance sheet
Total assets2,9482,8372,6782,8242,8442,5942,4942,513
Liabilities703706645663683658650680
Equity2,2442,1312,0342,1612,1611,9361,8441,834
Cash217184164376482226281305
Cash flow
Operating cash flow24021149290334252308280
Capital expenditure-4.0-3.0-2.8-1.5-1.2-1.5-6.8-2.5
Free cash flow23620846289332250301277

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2017 at +103.9%, weakest 2018 at −35.3%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
29 Oct 2026$0.85
5 Aug 2026$0.82
5 May 2026$0.79
10 Feb 2026$0.88
4 Nov 2025$0.69
28 Jul 2025$0.65
13 May 2025$0.55
11 Feb 2025$0.48
29 Oct 2024$0.40
6 Aug 2024$0.77
30 Apr 2024$0.12
6 Feb 2024$0.27

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€14bn
Market cap in trading currency
$15.8bn
Enterprise value
$14.9bn
P/E
19.4
P/S
6.32
P/B
8.60
EV/Sales
5.96
EV/EBITDA
14.4
Earnings yield
5.2%
FCF yield
7.4%

Results (last four quarters)

Revenue
$2.50bn
Gross profit
$2.40bn
EBITDA
$1.03bn
Net income
$885m
Earnings per share
$3.34
Revenue per share
$10.23
Revenue growth
+10.2%
Earnings growth
+12.7%

Profitability

Gross margin
96.3%
Operating margin
40.2%
Net margin
35.5%
Return on equity
44.3%
Return on assets
35.2%

Balance sheet and cash flow

Cash
$892m
Cash per share
$3.66
Financial debt
–
Debt/equity %
–
Current ratio
3.21
Book value per share
$7.52
Operating cash flow
$1.17bn
Free cash flow
$1.16bn

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
244m
Volume
2.10m
Avg. volume 3 months
2.41m
Relative volume
0.9

Price and technicals

Price
$64.63
1 day
−1.8%
52-week high
$72.75
52-week low
$40.74
Distance to 52-week high
−11.2%
Distance to 52-week low
+58.6%
Distance to 50-day line
+2.3%
Distance to 200-day line
+22.3%
RSI (14)
43
Volatility 1M
38.2%

Performance

1 week
−6.3%
1 month
−1.0%
3 months
+18.5%
6 months
+28.9%
YTD
+47.5%
1 year
+53.4%

Dates

Fiscal year end
2 Jan 2026
Most recent quarter
2 Oct 2026

Frequently asked questions

How has EXEL performed since 11/2016?

$10,000 grew to $37,641 by 20 Nov 2026, which is +14.2% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is EXEL?

Volatility was 40.6% per year, measured on monthly returns. The largest decline from a peak was −57.2%, with the low in 10/2018.

How does EXEL compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, EXEL returned +14.2% at 40.6%. The correlation of monthly returns was 0.25; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Exelixis, Inc. (EXEL): Return and risk | Portfolio Lab